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background: Although platelets are known to play a role in hemostasis, they also promote angiogenesis and tissue recovery by releasing 
various cytokines. Here, we examined autologous ‘activated platelet supernatant (APS)’ as a priming agent for stem cells; thereby enhance their 
proangiogenic potential and efficacy of stem cell-based therapy against ischemic diseases.
methods: Granulocyte-colony stimulating factor mobilized peripheral blood stem cells (mobPBSC) were isolated from healthy volunteers, while APS 
was collected separately by thrombin (0.5IU/L) activation of the platelet rich plasma. The characteristics of APS-primed mobPBSCs were examined 
and the 36-hour cell culture supernatant was measured to check the paracrine effect of APS-primed mobPBSCs. We used athymic mice ischemic 
hindlimbs and Matrigel plugs as in vivo models. Safety analysis for clinical application was done by checking the platelet activity of whole blood 
mixed with APS-primed mobPBSCs.
results: APS contained high levels of various angiogenic cytokines such as IL8, PDGF and VEGF. 6-hour mobPBSC priming with APS increased the 
expression of angiogenic factors such as CXCR4, CD34 and cell surface integrin b1, b2 subunits. This enabled APS-primed mobPBSCs to promote 
transwell migration to SDF-1 and increase adhesion to fibronectin and HUVECs. APS-primed mobPBSCs were also polarized toward CD14++/
CD16+ pro-angiogenic monocytes. The supernatant of 36-hour cultured APS-primed mobPBSCs contained high levels of IL8, IL10, IL17 and TNFa, 
which augmented proliferation and capillary network formation in HUVECs. In vivo transplantation of APS-primed mobPBSCs into athymic mice 
ischemic hindlimbs and Matrigel plugs elicited vessel differentiation, which improved vasculogenesis and tissue repair. Safety analysis of APS-primed 
mobPBSC showed platelet activity increased when APS-primed mobPBSCs were mixed in whole blood. However pretreatment with aspirin could 
decrease platelet activity.
Conclusions: Collectively, our data identify that APS priming can enhance the angiogenic potential of mobPBSCs, which can be used as a novel 
method in increasing efficacy of stem cell-based therapy for ischemic diseases.
